Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.

JNJ-38877618 is a potent, highly selective, orally bioavailable Met kinase inhibitor with IC50s of 2 and 3 nM for wild type and mutant Met, respectively.

NVP-BVU972 is a potent and selective c-Met inhibitor with IC50 of 14 nM with antitumor effects.

Glumetinib is a novel, potent and highly selective inhibitor of c-Met.

Ningetinib tosylate is an inhibitor of tyrosine kinase inhibitor (TKI) and the IC50 for c-Met, VEGFR2 and Axl are 6.7 nM, 1.9 nM and <1.0 nM respectively.

Tivantinib is an non-ATP-competitive c-Met inhibitor with Ki of 0.355 μM with little activity to Ron, and no inhibition to EGFR, InsR, PDGFRα or FGFR1/4.

Dihexa is a blood-brain barrier-permeable angiotensin IV analog which exhibits high affinity to HGF with Kd value of 65pM and induces c-Met phosphorylation in the presence of subthreshold concentrations of HGF and augment HGF-dependent cell scattering.

c-Met/RON Dual Kinase Inhibitor is a potent inhibitor against the kinase activities of HGF receptor c-Met and MSP (Macrophage Stimulating Protein) receptor RON with IC50 of 4 and 9 nM, respectively, and it is reported to inhibit NIH3T3 TRP-Met and U-87 tumor growth in mice in vivo in a dose-dependent manner.

JNJ-38877605 is an ATP-competitive inhibitor of c-Met with IC50 of 4 nM.

MK8033 HCl is a specific dual ATP competitive c-Met/Ron inhibitor (IC50=1 nM Wt c-Met) under investigation as a treatment for cancer.